IRIS
TOMELLERI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.278
EU - Europa 1.018
NA - Nord America 982
SA - Sud America 243
AF - Africa 20
Continente sconosciuto - Info sul continente non disponibili 4
Totale 3.545
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 928
SG - Singapore 501
CN - Cina 411
RO - Romania 264
IT - Italia 229
BR - Brasile 207
HK - Hong Kong 179
SE - Svezia 169
DE - Germania 114
VN - Vietnam 63
RU - Federazione Russa 55
GB - Regno Unito 39
FI - Finlandia 38
CA - Canada 33
IN - India 24
FR - Francia 22
JP - Giappone 20
PH - Filippine 20
AR - Argentina 17
PL - Polonia 17
ES - Italia 16
MX - Messico 16
AT - Austria 14
NL - Olanda 13
BD - Bangladesh 10
ZA - Sudafrica 9
TR - Turchia 8
ID - Indonesia 7
LT - Lituania 7
EC - Ecuador 5
EG - Egitto 5
MK - Macedonia 5
CO - Colombia 4
IE - Irlanda 4
IR - Iran 4
UZ - Uzbekistan 4
XK - ???statistics.table.value.countryCode.XK??? 4
AE - Emirati Arabi Uniti 3
IQ - Iraq 3
KR - Corea 3
PY - Paraguay 3
UA - Ucraina 3
AL - Albania 2
BE - Belgio 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
IL - Israele 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
PE - Perù 2
PK - Pakistan 2
SA - Arabia Saudita 2
UY - Uruguay 2
VE - Venezuela 2
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
CL - Cile 1
GE - Georgia 1
HR - Croazia 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
LV - Lettonia 1
MA - Marocco 1
PR - Porto Rico 1
SN - Senegal 1
TG - Togo 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 3.545
Salva come PNG Salva come JPEG
Città #
Singapore 248
Dallas 202
Hong Kong 175
Ashburn 139
Shanghai 114
Hefei 63
Beijing 62
Milan 62
Munich 59
New York 59
Los Angeles 39
Boardman 38
Lawrence 31
Princeton 31
São Paulo 31
Ho Chi Minh City 28
Moscow 23
Helsinki 19
Rome 19
Nuremberg 18
Atlanta 14
Montreal 14
Warsaw 14
Denver 13
Tokyo 13
Turku 13
Cesano Boscone 12
Chicago 10
Guangzhou 10
Brooklyn 9
London 9
Makati City 9
Pune 9
Stockholm 9
Chennai 8
Hanoi 8
Johannesburg 8
Naples 8
Phoenix 8
Poplar 8
Rio de Janeiro 8
Santa Clara 8
Shenzhen 8
Ankara 7
Falkenstein 6
Lappeenranta 6
Orem 6
Toronto 6
Ancona 5
Boston 5
Council Bluffs 5
Florence 5
Frankfurt am Main 5
Querétaro 5
Verona 5
Vittoria 5
Wolfhagen 5
Bari 4
Brasília 4
Dublin 4
Goito 4
Haiphong 4
Houston 4
Jiaxing 4
Manchester 4
Mexico City 4
Pisa 4
Pristina 4
Quezon City 4
Seattle 4
Skopje 4
Taizhou 4
Tashkent 4
The Dalles 4
Trento 4
Valencia 4
Vienna 4
Zhengzhou 4
Alessandria 3
Annapolis 3
Baie-D'Urfé 3
Bauru 3
Brescia 3
Cabanatuan City 3
Cairo 3
City of London 3
Formiga 3
Fortaleza 3
Foshan 3
Joinville 3
Osaka 3
Osimo 3
Roubaix 3
San Francisco 3
Santo André 3
Tianjin 3
Topeka 3
Turin 3
Vancouver 3
Villafranca Padovana 3
Totale 1.916
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 325
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 107
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 106
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 106
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 94
A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM) 86
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 82
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 78
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 77
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 76
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 72
Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort 71
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 67
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 66
Clinically isolated aortitis successfully treated with methotrexate monotherapy 65
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 65
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 65
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 64
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 64
Drug retention rates of biological agents in adult onset Still's disease 64
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 63
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 63
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 62
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients 61
Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort 61
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 61
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 59
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 59
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 56
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 56
LONG-TERM PATHOPHYSIOLOGIC AND PROGNOSTIC EVALUATION OF DIFFERENT DISEASE SUBSETS IN GIANT CELL ARTERITIS 55
An enlightening scan 55
VEXAS associated acute disseminated Encephalo-Myelitis (ADEM)-like syndrome: A case report and review of the literature 52
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 52
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 52
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management 49
Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India 49
HETEROGENEITY OF CYTOPENIAS IN VEXAS SYNDROME: A SINGLE CENTRE EXPERIENCE 46
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 46
The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort 44
Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey 42
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 41
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic 41
Clinical and dermoscopic description of accelerated nodulosis after tocilizumab treatment for an isolated aortitis with coronary involvement 40
Response to: 'Correspondence on Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: A monocentric survey' by Comarmond et al 38
Potential acceptance of COVID-19 vaccine in rheumatological patients: A monocentric comparative survey 38
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance 36
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 35
Failure of first anti-TNF agent in Takayasu’s arteritis: To switch or to swap? 35
Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study 35
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 35
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement 35
Multimodal chorioretinal imaging in erdheim-chester disease 33
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis 33
Efficacy of interleukin-1 blockade with anakinra in the management of post-COVID-19 steroid-dependent multisystem inflammatory syndrome: a case report 31
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 31
One year later: The case of tocilizumab in COVID-19 30
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients 30
The target on B cells in Systemic Sclerosis: a “midsummer dream” to extinguish inflammation and prevent early disease progression to fibrosis 27
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease 26
Myocardial infarction in giant cell arteritis: It is all a matter of balance 26
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply 26
Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease 21
Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort 19
Spontaneous coronary-artery dissection 18
Totale 3.703
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.549
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.549
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202115 0 0 0 0 0 4 3 3 0 0 3 2
2021/202264 0 0 23 17 2 4 6 2 4 3 0 3
2022/2023305 75 58 15 3 8 36 29 38 19 10 9 5
2023/2024403 11 30 52 36 34 59 33 44 3 7 15 79
2024/20251.367 100 29 44 39 68 89 408 118 161 103 91 117
2025/20261.528 256 229 258 483 295 7 0 0 0 0 0 0
Totale 3.703